Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Febuxostat Related Intermediates: Febuxostat CAS 144060-53-7 Ethyl 2-Chloroacetoacetate CAS 609-15-4 4-Hydroxythiobenzamide CAS 25984-63-8 Ethyl 2-(3-Cyano-4-Hydroxyphenyl)-4-Methyl-1,3-Thiazole-5-Carboxylate CAS 161798-02-3 Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5-Thiazolecarboxylate CAS 160844-75-7 Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-01-2 Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-03-4 Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161797-99-5| Item | Specifications |
| Appearance | Light Yellow to Off-White Powder |
| Identification | By HPLC; By HNMR |
| Loss on Drying | <0.50% |
| Residue on Ighition | <0.30% |
| Single Impurity | <0.50% |
| Total Impurities | <1.00% |
| Purity / Analysis Method | >99.0% (by HPLC) |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Febuxostat (CAS: 144060-53-7) |
Description:
Specifications:
Package & Storage:
| Chemical Name | Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate |
| Synonyms | Febuxostat Intermediate |
| CAS Number | 161797-99-5 |
| CAT Number | RF-PI1122 |
| Stock Status | In Stock, Production Capacity 100 Tons/Year |
| Molecular Formula | C13H13NO3S |
| Molecular Weight | 263.31 |
| Melting Point | 180℃ |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate (CAS: 161797-99-5) is used in the synthesis of Febuxostat (CAS: 144060-53-7), a xanthine oxidase/xanthine dehydrogenase inhibitor. Used for treatment of hyperuricemia and chronic gout. 40-120 mg/day febuxostat was proven effective in lowering serum urate levels when administered to manage hyperuricemia in patients with gout. Fabuxostat was discovered by Teijin Pharmaceuticals and licensed to TAP Pharmaceuticals (which is currently part of Takeda Pharmaceuticals) and was approved in the U.S. for the treatment of hyperuricemia in patients with gout.
